Epinephrine Market - Size, Share, Outlook, and
Opportunity Analysis, 2018-2026
Epinephrine also called as adrenaline is a hormone and neurotransmitter produced by the
adrenal glands. Epinephrine helps to reverse the effects of anaphylaxis and it is used as the first
line of treatment. Auto-injectors are commonly used by individuals suffering from anaphylaxis,
as it can be administered by non- medical person.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2401
The global epinephrine market size was valued at US$ 2,040 million in 2017, and is expected
to exhibit a CAGR of 11.0% over the forecast period (2018 – 2026).
Increasing support from government and insurance agencies for generic products to propel
epinephrine market growth
Launch of cost effective generic epinephrine products by the manufacturers is majorly attributed
to the high price of EpiPen developed by Mylan NV. The price hike was not accepted by the
public, as the drug price increased to more than 400% over a decade.
According to data provided by Elsevier Clinical Solutions’ Gold Standard Drug Database, 2016,
the cost of EpiPen was US$ 103.50 in 2009, where the price increased up to US$ 264.50 in
2013. The price of the product further increased by 75% costing around US$ 461 in 2015,
whereas the price reached to US$ 608.61 in 2016.
Furthermore, support of regulatory agencies is expected to streamline the approval of generic
copies of drugs, thus allowing the launch of drug substitutes without affecting the clinical effect
or safety profile. For instance, in October 2017, the commissioner of FDA announced plans to
accelerate development of generic versions that combine a drug and a device. In November
2017, the FDA issued guidance for developing generic copies of complex medicines such as
EpiPen to reach the market, without affecting safety and efficacy, thereby providing a lower-
cost option and to meet the demand of drug shortages.